Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
By 2016, the above firm transportation portfolio provides Antero the ability to direct 49% of its production to the Gulf Coast, 28% to Appalachia and 23% to Midwest pricing, including Chicago and Detroit. Antero's all-in average firm transportation and firm sales cost per MMbtu assuming full utilization, including both demand and commodity charges, is $0.31, $0.32 and $0.42 for 2014, 2015 and 2016, respectively. The firm transportation portfolio, based on current futures pricing and differentials, would result in an approximate $0.15 per MMbtu basis differential improvement in its 2016 realized prices compared to 2014 realized prices.
I got mostly out above $20
Looking for re-entry as I think this is mostly the sector selling off.
Tuesday's are usually good here.
I'm in here at 29.89 average
Looking for the morning rally to get this near $31
Antero’s oil and gas wells are located in the Utica and Marcellus shale regions of Ohio, Pennsylvania and West Virginia. Although it has lowered some of its expectations for the Utica, it still estimates producing 783 to 787 millions of cubic feet per day of natural gas, up 105 percent from 2013’s first quarter and up 16 percent from the previous quarter.
Today was typical market over-reaction to the first part of above without consideration for the second part.
I took advantage and loaded up on the dip.
Good luck to all longs here!
Sold at $2.74 for a nice gain from 2.20
I'm down huge here!!!!!
This is nuts
Up nicely here so far
Down big here. Thinking of buying more?
I'm down huge here.
Bought some more at 29.61
I bought at 29.95
Just bought more at $11.80
I'm buying today if it slips below. $30
Agree
This is an excellent re-entry level.
IMO we are headed to $20 range with the news of re-submission
CRMMF has been holding even with the recent biotech downturn.
Still low volume but earnings report is due out April 24 and should be yet another positive report.
IMO, this one will catch fire soon enough.
Just took a position here at 2.2097
Management has really screwed this up IMO.
They have killed the momentum with the announcement that they want a huge number of additional shares at the May 7 vote.
Why not wait until the price was higher into the June ADCOM?
It's hard to believe we were trading in the $2.40's not too long ago.
Congrats directors! Your untimely announcement has stabbed us all in the back!
I think the market is generally red but also, the fear of the extra shares here is playing a role
Yes
Crazy!!!
Hopefully , we will be rewarded soon.
OGXI
Just doubled down at 10.12
CYTK
Just picked some up at $8.80
Looks like a good day to buy
ETRM
OGXI
Most bio's are on sale today
ETRM volume today of 1.2 million shares.
Volume before price here!
ETRM
StRting the April run.
IMO we move towards $3 by end of May as we approach ADCOM in June
ETRM
PreMarket action around $1.97 this AM
I don't think it goes that low.
I think April will see the start of the run up here.
Study will evaluate the prevention of delayed-onset chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
REDWOOD CITY, Calif.--(BUSINESS WIRE)--March 31, 2014--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL(TM) (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy. This Phase 3 clinical trial will evaluate SUSTOL for the prevention of delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents and is designed to support expansion of the expected label for SUSTOL in the delayed-onset HEC setting.
The label-expansion study is a prospective, randomized, placebo-controlled two-arm study of approximately 1000 HEC-treated patients comparing SUSTOL plus the NK-1 inhibitor fosaprepitant and dexamethasone to ondansetron plus fosaprepitant and dexamethasone. Currently, there is no long-acting 5-HT(3) receptor antagonist approved for the prevention of delayed-onset CINV after the administration of HEC agents. Published results of large clinical trials show that approximately 35 percent of patients receiving HEC agents experience CINV in the delayed phase with the currently available standard three-drug regimen, leaving a significant unmet medical need for better therapy. Based on the results of a previously completed Phase 3 trial, Heron is currently pursuing the approval of SUSTOL for the prevention of acute and delayed CINV in patients receiving moderately emetogenic chemotherapy (MEC) agents and the prevention of acute CINV in HEC. The Company anticipates submission of a new drug application (NDA) for SUSTOL to the U.S. Food and Drug Administration (FDA) mid-2014.
"We are excited to have this important label-expansion study underway, which is focused on an area of significant unmet medical need," commented Barry D. Quart, PharmD, Chief Executive Officer of Heron Therapeutics. "Based on very strong interest from community oncologists, we anticipate rapid enrollment, with data to be available before the end of 2014. Furthermore, if successful, this study will allow us to further differentiate SUSTOL as the only 5-HT(3) receptor antagonist with demonstrated activity for the prevention of delayed-onset CINV in patients receiving the most highly emetogenic chemotherapy agents."
About SUSTOL
Heron's lead product candidate, SUSTOL(TM) (formerly known as APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT(3) antagonist approved for the prevention of delayed-onset CINV in patients receiving moderately emetogenic chemotherapy (MEC); none are approved for delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC). SUSTOL contains the 5-HT(3) receptor antagonist granisetron formulated in the Company's proprietary Biochronomer(TM) polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.
I may grab a starter position here this week?
Q2 should be good here IMO
ETRM should be setting up for a nice bounce.
I'm thinking that we will start seeing this move up in April with the ADCOM date set for June 17
Looking forward for Q2 to start on this one.
I continue to accumulate here. Averaging my cost down as I go.
It's only a matter of time before this bounces, and when it turns, it's going to run fast IMO
I actually did pick up a few more today.
Sounds like a plan
...Crickets.... Crickets.......
The company has been hitting their ATM.
That explains a lot of the selling pressure.
They only have about $3,000,000 more.
They project enough cash yo get them through 2015
IMO, once the selling is done in the next week or so, we should start to pop up fairly steadily.
This one will require a little more patience
Yes
It is implanted laparoscopically.
I meant there is no change in the native anatomy. There is no irreversible change in the patient's digestive tract.
Looking forward to a reversal here after a healthy pullback.
Should get moving back into the $80's with the release of Captain America
ETRM
I appreciate the discussion on surgical approaches to weight loss, but the point here is VBLOC is a non-surgical option and the patient's anatomy is preserved.
The comparison of VBLOC with Bariatric surgery is really like comparing apples and oranges.
To me, this is a catalyst play, pure and simple. The June 17 ADCOM date should fuel the run up here to close to $3
Good luck to all of us longs.
Yes
It's like being a massive sale.
Everything seems to be on the sale rack IMO.
Looks like a massive opportunity for those of us with a good cash position.
I'm a buyer here.
MEIP and HRTX were my only greens today. Everything else got hit pretty hard. Tough day in the market.
Yep
ETRM is way oversold right now.
I continue to be a buyer here.